Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study

This expanded access program (EAP) was designed to provide trabectedin access for patients with incurable soft tissue sarcoma (STS) following progression of disease with standard therapy. The outcomes of trial participants accrued over approximately 5 years are reported. Adult patients with advanced...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2013-06, Vol.24 (6), p.1703-1709
Hauptverfasser:	Samuels, B.L., Chawla, S., Patel, S., von Mehren, M., Hamm, J., Kaiser, P.E., Schuetze, S., Li, J., Aymes, A., Demetri, G.D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents, Alkylating - administration & dosage Antineoplastic Agents, Alkylating - adverse effects Biological and medical sciences Compassionate Use Trials - mortality Compassionate Use Trials - trends Dermatology Dioxoles - administration & dosage Dioxoles - adverse effects Disease Progression expanded access program Female Global Health - trends Health Services Accessibility - trends Humans Kaplan-Meier Estimate L-sarcoma Male Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) objective response rate overall survival Pharmacology. Drug treatments Sarcoma - drug therapy Sarcoma - mortality Sarcoma - pathology soft tissue sarcoma Tetrahydroisoquinolines - administration & dosage Tetrahydroisoquinolines - adverse effects Trabectedin Treatment Failure Treatment Outcome Tumors Tumors of the skin and soft tissue. Premalignant lesions Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!